Smith & Nephew plc (LON:SN.) was downgraded by analysts at Investec from an “add” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Analyst Ratings.Net reports. They currently have a GBX 802 ($12.24) price objective on the stock, up from their previous price objective of GBX 776 ($11.84).
SN. has been the subject of a number of other recent research reports. Analysts at Deutsche Bank reiterated a “hold” rating on shares of Smith & Nephew plc in a research note to investors on Monday. They now have a GBX 638 ($9.74) price target on the stock. Separately, analysts at JP Morgan Cazenove reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note to investors on Thursday, June 27th. Finally, analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew plc in a research note to investors on Wednesday, June 26th. They now have a GBX 800 ($12.21) price target on the stock.
Eight research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of GBX 767.50 ($11.71).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON: SN) and advanced wound management.